 Michael Rosenberg
Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Long QT Syndrome | 9 | 2025 | 69 | 4.920 |
Why?
| | Atrial Fibrillation | 13 | 2026 | 551 | 3.180 |
Why?
| | Machine Learning | 8 | 2023 | 587 | 1.800 |
Why?
| | Electrocardiography | 10 | 2024 | 663 | 1.710 |
Why?
| | Electronic Health Records | 6 | 2025 | 1174 | 1.440 |
Why?
| | Anti-Arrhythmia Agents | 3 | 2023 | 141 | 1.320 |
Why?
| | Body Height | 5 | 2017 | 199 | 1.240 |
Why?
| | Multifactorial Inheritance | 2 | 2024 | 190 | 1.220 |
Why?
| | Decision Support Systems, Clinical | 2 | 2025 | 267 | 1.160 |
Why?
| | Torsades de Pointes | 4 | 2024 | 23 | 1.060 |
Why?
| | Ventricular Premature Complexes | 2 | 2025 | 37 | 1.030 |
Why?
| | Cardiomyopathies | 2 | 2025 | 334 | 0.980 |
Why?
| | Defibrillators, Implantable | 7 | 2020 | 381 | 0.930 |
Why?
| | Phenethylamines | 2 | 2024 | 19 | 0.830 |
Why?
| | Catheter Ablation | 6 | 2026 | 351 | 0.790 |
Why?
| | Tachycardia, Ventricular | 4 | 2022 | 180 | 0.740 |
Why?
| | Death, Sudden, Cardiac | 6 | 2019 | 230 | 0.730 |
Why?
| | Arrhythmias, Cardiac | 4 | 2019 | 355 | 0.690 |
Why?
| | Medical Order Entry Systems | 1 | 2021 | 40 | 0.650 |
Why?
| | Sulfonamides | 2 | 2024 | 579 | 0.620 |
Why?
| | Sotalol | 1 | 2019 | 13 | 0.610 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2025 | 392 | 0.610 |
Why?
| | Risk Factors | 20 | 2026 | 10783 | 0.600 |
Why?
| | Atrial Flutter | 3 | 2025 | 45 | 0.590 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2134 | 0.590 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2022 | 250 | 0.590 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 170 | 0.580 |
Why?
| | Tachycardia, Supraventricular | 2 | 2021 | 45 | 0.570 |
Why?
| | Aged | 23 | 2026 | 25901 | 0.570 |
Why?
| | Risk Assessment | 7 | 2025 | 3680 | 0.560 |
Why?
| | Dihydrotestosterone | 1 | 2018 | 39 | 0.550 |
Why?
| | Pacemaker, Artificial | 4 | 2023 | 126 | 0.520 |
Why?
| | Electrocardiography, Ambulatory | 2 | 2019 | 63 | 0.510 |
Why?
| | Heart Rate | 2 | 2025 | 849 | 0.500 |
Why?
| | Peptide Fragments | 3 | 2014 | 691 | 0.450 |
Why?
| | Decision Support Techniques | 1 | 2019 | 460 | 0.450 |
Why?
| | Humans | 48 | 2026 | 144298 | 0.450 |
Why?
| | Accessory Atrioventricular Bundle | 1 | 2014 | 13 | 0.420 |
Why?
| | Endonucleases | 1 | 2014 | 34 | 0.420 |
Why?
| | Procollagen | 1 | 2014 | 24 | 0.410 |
Why?
| | Male | 31 | 2026 | 72263 | 0.410 |
Why?
| | Female | 30 | 2026 | 78137 | 0.400 |
Why?
| | Heart Failure | 2 | 2023 | 2323 | 0.390 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 176 | 0.380 |
Why?
| | Myocardial Infarction | 1 | 2020 | 1209 | 0.370 |
Why?
| | Heart Failure, Diastolic | 1 | 2012 | 24 | 0.370 |
Why?
| | Genome-Wide Association Study | 3 | 2018 | 1373 | 0.370 |
Why?
| | Middle Aged | 17 | 2025 | 35892 | 0.370 |
Why?
| | Incidence | 6 | 2021 | 2886 | 0.360 |
Why?
| | Exercise | 3 | 2026 | 2183 | 0.350 |
Why?
| | Coronary Disease | 1 | 2013 | 381 | 0.340 |
Why?
| | Atrioventricular Block | 2 | 2023 | 44 | 0.340 |
Why?
| | Atherosclerosis | 1 | 2013 | 408 | 0.300 |
Why?
| | Transcatheter Aortic Valve Replacement | 2 | 2023 | 153 | 0.290 |
Why?
| | Aortic Valve Stenosis | 2 | 2023 | 255 | 0.280 |
Why?
| | Inpatients | 2 | 2025 | 545 | 0.270 |
Why?
| | Echocardiography | 2 | 2025 | 644 | 0.270 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2348 | 0.250 |
Why?
| | Proportional Hazards Models | 5 | 2018 | 1322 | 0.250 |
Why?
| | Heart Conduction System | 2 | 2024 | 95 | 0.240 |
Why?
| | Case-Control Studies | 3 | 2024 | 3595 | 0.230 |
Why?
| | Arterial Switch Operation | 1 | 2025 | 15 | 0.230 |
Why?
| | Tricuspid Valve | 1 | 2025 | 41 | 0.230 |
Why?
| | Transposition of Great Vessels | 1 | 2025 | 40 | 0.220 |
Why?
| | Stroke Volume | 2 | 2025 | 650 | 0.210 |
Why?
| | Logistic Models | 2 | 2020 | 2112 | 0.200 |
Why?
| | Basketball | 1 | 2023 | 17 | 0.200 |
Why?
| | Retrospective Studies | 13 | 2026 | 17104 | 0.200 |
Why?
| | Longitudinal Studies | 3 | 2018 | 2940 | 0.190 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2014 | 109 | 0.180 |
Why?
| | Electric Countershock | 1 | 2023 | 127 | 0.180 |
Why?
| | Metoprolol | 1 | 2022 | 26 | 0.180 |
Why?
| | Pilot Projects | 3 | 2018 | 1880 | 0.180 |
Why?
| | Diastole | 2 | 2012 | 142 | 0.180 |
Why?
| | United States | 6 | 2019 | 15979 | 0.180 |
Why?
| | Tachycardia, Atrioventricular Nodal Reentry | 1 | 2021 | 28 | 0.170 |
Why?
| | Prospective Studies | 5 | 2019 | 7972 | 0.170 |
Why?
| | Sex Factors | 3 | 2018 | 2103 | 0.170 |
Why?
| | Adult | 9 | 2025 | 40408 | 0.170 |
Why?
| | Cluster Analysis | 1 | 2022 | 516 | 0.170 |
Why?
| | Time Factors | 4 | 2025 | 7128 | 0.160 |
Why?
| | Biomarkers | 3 | 2018 | 4248 | 0.150 |
Why?
| | Drug Dosage Calculations | 1 | 2019 | 27 | 0.150 |
Why?
| | Hypertension | 2 | 2022 | 1259 | 0.150 |
Why?
| | Contraindications, Procedure | 1 | 2019 | 12 | 0.150 |
Why?
| | Myostatin | 2 | 2009 | 24 | 0.150 |
Why?
| | Cell Phone | 1 | 2020 | 82 | 0.150 |
Why?
| | Bradycardia | 1 | 2019 | 61 | 0.150 |
Why?
| | Tachycardia | 2 | 2021 | 57 | 0.150 |
Why?
| | Treatment Outcome | 7 | 2026 | 11713 | 0.150 |
Why?
| | Decision Trees | 1 | 2018 | 79 | 0.140 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2018 | 50 | 0.140 |
Why?
| | Artificial Intelligence | 1 | 2023 | 381 | 0.140 |
Why?
| | Nonlinear Dynamics | 1 | 2018 | 95 | 0.130 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2113 | 0.130 |
Why?
| | Body Weights and Measures | 1 | 2016 | 37 | 0.120 |
Why?
| | Metabolic Diseases | 1 | 2017 | 114 | 0.120 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5862 | 0.120 |
Why?
| | Drug Monitoring | 1 | 2019 | 396 | 0.120 |
Why?
| | Patient Safety | 1 | 2019 | 351 | 0.120 |
Why?
| | Down-Regulation | 1 | 2018 | 613 | 0.120 |
Why?
| | Frailty | 1 | 2019 | 199 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2012 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2024 | 5404 | 0.110 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2015 | 63 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 241 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1537 | 0.110 |
Why?
| | Physicians | 1 | 2023 | 948 | 0.100 |
Why?
| | Sirtuin 2 | 1 | 2014 | 27 | 0.100 |
Why?
| | Prosthesis Implantation | 1 | 2015 | 153 | 0.100 |
Why?
| | Cardiac Pacing, Artificial | 2 | 2023 | 84 | 0.100 |
Why?
| | Primary Prevention | 1 | 2015 | 217 | 0.100 |
Why?
| | Algorithms | 1 | 2021 | 1839 | 0.100 |
Why?
| | Atrial Function, Left | 1 | 2012 | 9 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 325 | 0.090 |
Why?
| | Longevity | 1 | 2014 | 173 | 0.090 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 89 | 0.090 |
Why?
| | Recurrence | 2 | 2026 | 1134 | 0.090 |
Why?
| | Prognosis | 2 | 2018 | 4293 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 832 | 0.090 |
Why?
| | Fibrosis | 1 | 2014 | 547 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2019 | 8265 | 0.080 |
Why?
| | Nuclear Receptor Co-Repressor 1 | 1 | 2011 | 11 | 0.080 |
Why?
| | Receptors, Thyroid Hormone | 1 | 2011 | 18 | 0.080 |
Why?
| | Prevalence | 1 | 2018 | 2836 | 0.080 |
Why?
| | Echocardiography, Doppler | 1 | 2011 | 114 | 0.080 |
Why?
| | Age Factors | 1 | 2018 | 3324 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 750 | 0.080 |
Why?
| | Thyroid Hormones | 1 | 2011 | 68 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2009 | 317 | 0.080 |
Why?
| | Thyroid Gland | 1 | 2011 | 88 | 0.080 |
Why?
| | Population Surveillance | 1 | 2013 | 483 | 0.080 |
Why?
| | Blood Flow Velocity | 1 | 2011 | 419 | 0.080 |
Why?
| | Heart | 2 | 2010 | 625 | 0.080 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2011 | 196 | 0.070 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 845 | 0.070 |
Why?
| | Cardiomegaly | 1 | 2010 | 174 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 966 | 0.070 |
Why?
| | Anti-Infective Agents, Local | 1 | 2009 | 40 | 0.070 |
Why?
| | Ventricular Fibrillation | 1 | 2009 | 64 | 0.070 |
Why?
| | Aortic Valve | 2 | 2023 | 364 | 0.070 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2009 | 214 | 0.070 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2009 | 140 | 0.070 |
Why?
| | Gene Deletion | 1 | 2009 | 388 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 435 | 0.060 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2010 | 452 | 0.060 |
Why?
| | Young Adult | 2 | 2023 | 14092 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2019 | 2939 | 0.060 |
Why?
| | Myocytes, Cardiac | 1 | 2010 | 538 | 0.060 |
Why?
| | Ethanol | 1 | 2009 | 625 | 0.050 |
Why?
| | Bundle of His | 1 | 2023 | 19 | 0.050 |
Why?
| | Bundle-Branch Block | 1 | 2023 | 36 | 0.050 |
Why?
| | Heart Atria | 1 | 2024 | 140 | 0.050 |
Why?
| | Mice | 5 | 2014 | 18218 | 0.050 |
Why?
| | Nebivolol | 1 | 2022 | 9 | 0.040 |
Why?
| | Action Potentials | 1 | 2025 | 501 | 0.040 |
Why?
| | Atrioventricular Node | 1 | 2021 | 15 | 0.040 |
Why?
| | Focus Groups | 1 | 2023 | 566 | 0.040 |
Why?
| | Remote Sensing Technology | 1 | 2020 | 19 | 0.040 |
Why?
| | Electronics | 1 | 2020 | 69 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2014 | 3106 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 603 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1935 | 0.030 |
Why?
| | Survival Analysis | 2 | 2014 | 1368 | 0.030 |
Why?
| | Body Mass Index | 2 | 2017 | 2417 | 0.030 |
Why?
| | Blotting, Western | 2 | 2011 | 1160 | 0.030 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 54 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2018 | 374 | 0.030 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 91 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 997 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1076 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2014 | 88 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2081 | 0.030 |
Why?
| | NAD | 1 | 2014 | 82 | 0.030 |
Why?
| | Ventricular Remodeling | 1 | 2015 | 275 | 0.020 |
Why?
| | Cohort Studies | 2 | 2017 | 5948 | 0.020 |
Why?
| | Blood Glucose | 2 | 2016 | 2326 | 0.020 |
Why?
| | HeLa Cells | 1 | 2014 | 631 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1843 | 0.020 |
Why?
| | Animals | 5 | 2014 | 37800 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 1034 | 0.020 |
Why?
| | Lipids | 1 | 2016 | 702 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3408 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2011 | 54 | 0.020 |
Why?
| | Thyroxine | 1 | 2011 | 65 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2011 | 104 | 0.020 |
Why?
| | Hypothyroidism | 1 | 2011 | 67 | 0.020 |
Why?
| | Thyrotropin | 1 | 2011 | 118 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 318 | 0.020 |
Why?
| | Health Behavior | 1 | 2016 | 786 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2014 | 627 | 0.020 |
Why?
| | Bone Development | 1 | 2009 | 52 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1763 | 0.020 |
Why?
| | Hypertrophy | 1 | 2009 | 128 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4554 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2010 | 390 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2009 | 276 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6387 | 0.020 |
Why?
| | Tibia | 1 | 2009 | 175 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1046 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 240 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 971 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1565 | 0.020 |
Why?
| | Bone and Bones | 1 | 2009 | 317 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 770 | 0.010 |
Why?
| | Gene Expression | 1 | 2011 | 1474 | 0.010 |
Why?
| | Bone Density | 1 | 2009 | 483 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2010 | 2177 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2821 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5553 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5954 | 0.010 |
Why?
| | Inflammation | 1 | 2010 | 2862 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2500 | 0.010 |
Why?
|
|
Rosenberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|